» Articles » PMID: 8892899

Generation of Atypical Pulmonary Inflammatory Responses in BALB/c Mice After Immunization with the Native Attachment (G) Glycoprotein of Respiratory Syncytial Virus

Overview
Journal J Virol
Date 1996 Nov 1
PMID 8892899
Citations 63
Authors
Affiliations
Soon will be listed here.
Abstract

The feasibility of using the highly purified native attachment (G) protein in a subunit vaccine against respiratory syncytial virus (RSV) was examined in a murine model with or without the fusion (F) protein of RSV and the adjuvant QS-21. The studies established that QS-21 was more potent than AIOH as an adjuvant for both F and G glycoproteins. Augmented antigen-dependent killer cell activity and complement-assisted serum neutralizing and anti-F and G protein immunoglobulin G2a antibody titers were observed. Immunization with G/QS-21 generated immune responses that were characterized by low levels of antigen-dependent killer cell activity, elevated levels of interleukin-5 (IL-5) and percentages of eosinophils in the bronchoalveolar lavage fluids after challenge, and splenic immunocytes that secreted IL-5 but not gamma interferon (IFN-gamma) after in vitro stimulation with purified whole virus antigens. The pulmonary eosinophilia was similar to that induced by a facsimile of a formalin-inactivated vaccine used in previous clinical trials and was prevented by prior in vivo treatment with anti-IL-5 but not with control immunoglobulin G or anti-IFN-gamma neutralizing monoclonal antibodies. Thus the data implied that vaccination with G/QS-21 generated helper T-cell immune responses that were type 2 in nature. Alternatively, the data suggested that the helper T-cell immune responses elicited by F/QS-21 were more type 1 in character. Neither eosinophilia nor elevated levels of IL-5 were observed in the lungs of mice after challenge. Noteworthy levels of antigen-dependent killer cell activity was observed, and splenic immunocytes secreted copious quantities of IFN-gamma. Immunization with a combination vaccine composed of highly purified native F and G proteins plus QS-21 (F+G/QS-21) resulted in augmented complement-assisted serum neutralizing antibody titers compared with vaccination with either F/QS-21 or G/QS-21 alone. However, following vaccination with F+G/QS-21, the bronchoalveolar lavage fluids contained significant increases in IL-5 and percentages of eosinophils after challenge, the spleen cells appeared to secrete less IFN-gamma after in vitro stimulation, and there was no evidence of increased numbers of antigen-dependent killer cell precursors. Taken together, the data imply that native G protein influences the nature of the immune responses elicited by F/QS-21. The results therefore suggest that G, not F, protein has more potential to bias the host for atypical pulmonary inflammatory responses.

Citing Articles

Recombinant RSV G protein vaccine induces enhanced respiratory disease via IL-13 and mucin overproduction.

Kawahara E, Senpuku K, Kawaguchi Y, Yamamoto S, Yasuda K, Kuroda E NPJ Vaccines. 2024; 9(1):187.

PMID: 39394212 PMC: 11470036. DOI: 10.1038/s41541-024-00987-w.


Intranasal Vaccination with a Respiratory-Syncytial-Virus-Based Virus-like Particle Displaying the G Protein Conserved Region Induces Severe Weight Loss and Pathology upon Challenge with Wildtype Respiratory Syncytial Virus.

Terhuja M, Siddappa M, Lamichhane P, Meshram C, Snider T, Ritchey J Viruses. 2024; 16(6).

PMID: 38932136 PMC: 11209524. DOI: 10.3390/v16060843.


Non-glycosylated G protein with CpG ODN provides robust protection against respiratory syncytial virus without inducing eosinophilia.

Kawahara E, Shibata T, Hirai T, Yoshioka Y Front Immunol. 2024; 14:1282016.

PMID: 38169867 PMC: 10758452. DOI: 10.3389/fimmu.2023.1282016.


Vaccine-Associated Enhanced Disease and Pathogenic Human Coronaviruses.

Gartlan C, Tipton T, Salguero F, Sattentau Q, Gorringe A, Carroll M Front Immunol. 2022; 13:882972.

PMID: 35444667 PMC: 9014240. DOI: 10.3389/fimmu.2022.882972.


Immunopathology of RSV: An Updated Review.

Bergeron H, Tripp R Viruses. 2021; 13(12).

PMID: 34960746 PMC: 8703574. DOI: 10.3390/v13122478.


References
1.
Kim H, LEIKIN S, ARROBIO J, BRANDT C, Chanock R, PARROTT R . Cell-mediated immunity to respiratory syncytial virus induced by inactivated vaccine or by infection. Pediatr Res. 1976; 10(1):75-8. DOI: 10.1203/00006450-197601000-00015. View

2.
Connors M, Giese N, Kulkarni A, Firestone C, Morse 3rd H, Murphy B . Enhanced pulmonary histopathology induced by respiratory syncytial virus (RSV) challenge of formalin-inactivated RSV-immunized BALB/c mice is abrogated by depletion of interleukin-4 (IL-4) and IL-10. J Virol. 1994; 68(8):5321-5. PMC: 236482. DOI: 10.1128/JVI.68.8.5321-5325.1994. View

3.
Belshe R, Van Voris L, MUFSON M . Parenteral administration of live respiratory syncytial virus vaccine: results of a field trial. J Infect Dis. 1982; 145(3):311-9. DOI: 10.1093/infdis/145.3.311. View

4.
Walsh E, Schlesinger J, Brandriss M . Protection from respiratory syncytial virus infection in cotton rats by passive transfer of monoclonal antibodies. Infect Immun. 1984; 43(2):756-8. PMC: 264366. DOI: 10.1128/iai.43.2.756-758.1984. View

5.
Walsh E, Schlesinger J, Brandriss M . Purification and characterization of GP90, one of the envelope glycoproteins of respiratory syncytial virus. J Gen Virol. 1984; 65 ( Pt 4):761-7. DOI: 10.1099/0022-1317-65-4-761. View